Proost N - Search Results

1

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J. Ratz L, et al. Among authors: proost n. Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y. Breast Cancer Res. 2022. PMID: 35715861 Free PMC article.

2

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

van Amerongen R, Nawijn MC, Lambooij JP, Proost N, Jonkers J, Berns A. van Amerongen R, et al. Among authors: proost n. Oncogene. 2010 Jan 7;29(1):93-104. doi: 10.1038/onc.2009.310. Epub 2009 Oct 5. Oncogene. 2010. PMID: 19802005

3

Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.

Krimpenfort P, Song JY, Proost N, Zevenhoven J, Jonkers J, Berns A. Krimpenfort P, et al. Among authors: proost n. Nature. 2012 Feb 22;482(7386):538-41. doi: 10.1038/nature10790. Nature. 2012. PMID: 22358843

4

Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells.

Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Kwon MC, Proost N, Song JY, de Vries H, Badhai J, Sutherland K, Krimpenfort P, Michalak EM, Jonkers J, Berns A. Huijbers IJ, et al. Among authors: proost n. EMBO Mol Med. 2014 Feb;6(2):212-25. doi: 10.1002/emmm.201303297. Epub 2014 Jan 8. EMBO Mol Med. 2014. PMID: 24401838 Free PMC article.

5

Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E, Orkin S, Berns A, van Lohuizen M. Serresi M, et al. Among authors: proost n. Cancer Cell. 2016 Jan 11;29(1):17-31. doi: 10.1016/j.ccell.2015.12.006. Cancer Cell. 2016. PMID: 26766588 Free article.

6

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL, van Lohuizen M, Gargiulo G. Serresi M, et al. Among authors: proost n. J Exp Med. 2018 Dec 3;215(12):3115-3135. doi: 10.1084/jem.20180801. Epub 2018 Nov 28. J Exp Med. 2018. PMID: 30487290 Free PMC article.

7

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S. Barazas M, et al. Among authors: proost n. Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10. Cancer Res. 2019. PMID: 30530501 Free PMC article.

8

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

Nagel R, Avelar AT, Aben N, Proost N, van de Ven M, van der Vliet J, Cozijnsen M, de Vries H, Wessels LFA, Berns A. Nagel R, et al. Among authors: proost n. Mol Cancer Ther. 2019 Apr;18(4):762-770. doi: 10.1158/1535-7163.MCT-18-0972. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872379 Free PMC article.

9

SLC1A3 contributes to L-asparaginase resistance in solid tumors.

Sun J, Nagel R, Zaal EA, Ugalde AP, Han R, Proost N, Song JY, Pataskar A, Burylo A, Fu H, Poelarends GJ, van de Ven M, van Tellingen O, Berkers CR, Agami R. Sun J, et al. Among authors: proost n. EMBO J. 2019 Oct 4;38(21):e102147. doi: 10.15252/embj.2019102147. Epub 2019 Sep 16. EMBO J. 2019. PMID: 31523835 Free PMC article.

10

QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment.

Bresser K, Logtenberg MEW, Toebes M, Proost N, Sprengers J, Siteur B, Boeije M, Kroese LJ, Schumacher TN. Bresser K, et al. Among authors: proost n. Oncoimmunology. 2022 Mar 17;11(1):2049486. doi: 10.1080/2162402X.2022.2049486. eCollection 2022. Oncoimmunology. 2022. PMID: 35309731 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters